⌘K

ND Capital logo

ND Capital

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Series A

AIRNA logo
AIRNA

Biotech • RNA Editing Therapeutics

Venrock Healthcare Capital Partners logo
RTW Investments logo
Nextech Invest logo
ND Capital logo

Airna is a biotech company that specializes in RNA editing therapeutics, aiming to target diseases inaccessible through other methods, with its first program focusing on treating the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Series B
$155M
04/01/2025
Article
Constructive Bio logo
Constructive Bio

Synthetic genomics • Biofactories

Ahren logo
Paladin Capital Group logo
OMX Ventures logo
Fine Structure Ventures logo

Constructive Bio transforms living cells into biofactories for creating new biomolecules, aiming to revolutionize drug manufacturing and discovery through synthetic genomics.

Series A
$58M
09/26/2024
Article
Vandria logo
Vandria

Mitochondrial therapeutics • Small molecule

ND Capital logo

Vandria is a biotechnology company developing small molecule mitophagy inducers to treat age-related and chronic diseases.

Series A
$20.6M
12/14/2023
Article
H55 logo
H55

Electric Aviation • Propulsion Systems

Tippet Venture Partners logo
RTX Ventures logo
ND Capital logo

H55 is a Swiss company that develops and commercializes electric and hybrid propulsion systems and battery technologies for the aviation industry.

Series C
$49.1M
09/27/2023
Article
Partillion Bioscience logo
Partillion Bioscience

Life Science Tools • Single-Cell Analysis

ND Capital logo
Vertical Venture Partners logo
Paladin Capital logo

Partillion Bioscience is a life science tools company that develops a single-cell analysis platform using its proprietary Nanovial technology for screening individual cells based on functional information.

Seed
$5M
09/27/2023
Article
Airna logo
Airna

Biotech • RNA Editing Therapeutics

Novalis logo
ND Capital logo
Fast Track Initiative logo
Codon Capital logo

Airna is a biotech company that specializes in RNA editing therapeutics, aiming to target diseases inaccessible through other methods, with its first program focusing on treating the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Equity
$30M
09/19/2023
Article